Samsrita Labs Limited reported a standalone loss of ₹31.47 lakh for the quarter ended June 30, 2026 (Q1FY27), widening from the ₹11.87 lakh loss recorded in the preceding quarter. The Hyderabad-based healthcare company generated no revenue from operations during the period, mirroring the nil revenue figure from Q4FY26.

The Board of Directors approved the unaudited standalone and consolidated financial results in a meeting held on August 13, 2026. The financial statements were prepared in accordance with Ind AS and reviewed by statutory auditors MGR & Co Chartered Accountants.

Financial Performance

The company’s total expenses for the quarter stood at ₹31.47 lakh, a significant increase from ₹16.83 lakh in the preceding quarter. This rise was primarily driven by a jump in other expenses, which climbed to ₹21.55 lakh from ₹7.32 lakh in Q4FY26. Employee benefit expenses also increased to ₹9.80 lakh from ₹7.83 lakh.

While revenue from operations remained at zero, the company recorded other income of ₹3.15 lakh, consistent with the previous quarter. Consequently, total revenue was limited to this other income component.

Consolidated Results

On a consolidated basis, Samsrita Labs reported a net loss of ₹18.87 lakh for the quarter, an improvement from the ₹48.16 lakh loss in the preceding quarter. This improvement was largely due to the share of profit from associate companies, which contributed ₹12.60 lakh, compared to a share of loss of ₹36.29 lakh in Q4FY26.

The consolidated entity includes two associate companies: Krisani Bio Sciences Private Limited and Qrops Advisory Services Private Limited. The group’s share of profit after tax from these associates helped offset the parent company’s operational losses.

What the Numbers Show

The divergence between standalone and consolidated performance highlights the company’s reliance on its associate entities for current profitability. While the standalone unit incurred higher operating costs with no revenue generation, the equity pick-up from associates provided a critical buffer, reducing the consolidated loss by over 60% compared to the previous quarter. This structure suggests that near-term financial health is heavily dependent on the performance of Krisani Bio Sciences and Qrops Advisory Services rather than core standalone operations.

Samsrita Labs Limited has scheduled its 30th Annual General Meeting (AGM) for the financial year 2026-27 on Monday, August 10, 2026, at 11:00 a.m. through Video Conferencing (VC) or Other Audio-Visual Means (OAVM). The company has published the notice in newspapers on July 19, 2026, and engaged Link In Time India Private Limited (LIIPL) to facilitate remote e-voting and the virtual meeting platform.

The meeting follows regulations set by the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and the Ministry of Corporate Affairs General Circular No. 09/2024 dated September 19, 2024. Electronic copies of the Notice of AGM and Annual Report were dispatched to shareholders with registered email addresses on July 18, 2026. Physical copies will be sent only upon specific request.

Key AGM Details

Shareholders who have not voted remotely may exercise their right to vote during the meeting. Members who have not registered their email addresses are requested to register them with the depository participants or the company to receive electronic communications. The AGM notice and detailed instructions for participation are accessible on the company's official portal.